Effects of tyroservatide on histone acetylation in lung carcinoma cells

International Journal of Cancer

Volumn 128, Issue 2, 2011, Pages 460-472

  Xu, Qiong ^a   Lu, Rong ^a,b   Zhu, Zhi Feng ^a   Lv, Jun Qiang ^a   Wang, Li Juan ^a   Zhang, Wen ^a   Hu, Jin Wei ^a   Meng, Jie ^a   Lin, Gang ^b   Yao, Zhi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Shenzhen Kangzhe Pharmaceutical Co Ltd   (China)

Author keywords

cell cycle; chromatin immunoprecipitation; gene expression regulation; histone acetylation; tyroservatide

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE; HISTONE H3; HISTONE H4; MESSENGER RNA; PROTEIN P21; PROTEIN P27; TYROSERVATIDE; UNCLASSIFIED DRUG;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ACETYLATION; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; OLIGOPEPTIDES;

EID: 78649607708     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25346     Document Type: Article

References (33)

1. Jia J, Lu R, Zhou C, Zhao L, Fu Z, Zhu Z, Wang L, Zheng M, Yang J, Zhang Y, Yao Z,. Gene-chip analysis of the effect of tripeptide tyroservatide (YSV) on gene-expression in human hepatocarcinoma BEL-7402 tumors transplanted to nude mice. Mol Carcinog 2006; 45: 197-203. (Pubitemid 43358152)
2. Zheng M, Lu R, Che X, Li J, Zhou C, Wang L, Xu Q, Cao H, Li Q, Yao Z,. Tyroservatide therapy for tumor growth, invasion and metastasis of Lewis lung carcinoma and human lung carcinoma A549. Oncology 2006; 70: 418-26.
3. Zhu Z, Jia J, Lu R, Lu Y, Fu Z, Zhao L, Wang L, Jin M, Zhao L, Gao W, Yao Z,. Expression of PTEN, p27, p21 and AKT mRNA and protein in human BEL-7402 hepatocarcinoma cells in transplanted tumors of nude mice treated with the tripeptide tyroservatide (YSV). Int J Cancer 2006; 118: 1539-44.
4. Xie DX, Wu JH, Feng YD, Li XL, Tao DD, Gong JP,. Analysis of cell cycle checkpoints by cyclins/DNA flow cytometry. Ai Zheng 2005; 24: 1151-5.
5. Yoshida M, Kijima M, Akita M, Beppu T,. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265: 17174-9.
6. Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, Richon VM, LaQuaglia MP,. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res 2003; 9: 5749-55.
7. Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM, La Quaglia MP,. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 1999; 59: 4392-9.
8. Hahnen E, Eyupoglu IY, Brichta L, Haastert K, Trankle C, Siebzehnrubl FA, Riessland M, Holker I, Claus P, Romstock J, Buslei R, Wirth B, et al. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 2006; 98: 193-202.
9. Barltrop JA, Owen TC, Cory AH, Cory JG,. 5-(3-Carboxymethoxyphenyl)-2-(4, 5-dimethylthiazolyl)-3-(4-sulfophenyl)tetrazolium, inner salt (MTS) and related analogs of 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) reducing to purple water-soluble formazans as cell-viability indicators. Bioorg Med Chem Lett 1991; 1: 611-4.
10. Kortenhorst MS, Carducci MA, Shabbeer S,. Acetylation and histone deacetylase inhibitors in cancer. Cell Oncol 2006; 28: 191-222.
11. Roth SY, Denu JM, Allis CD,. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120.
12. Grunstein M,. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349-52.
13. Chen WJ, Chang CY, Lin JK,. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip). Biochem Pharmacol 2003; 65: 1777-85.
14. Kouzarides T,. Acetylation: a regulatory modification to rival phosphorylation? EMBO J 2000; 19: 1176-9.
15. Redner RL, Wang J, Liu JM,. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999; 94: 417-28.
16. Marmorstein R,. Structure of histone deacetylases: insights into substrate recognition and catalysis. Structure 2001; 9: 1127-33.
17. Lemercier C, Brocard MP, Puvion-Dutilleul F, Kao HY, Albagli O, Khochbin S,. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J Biol Chem 2003; 277: 22045-52.
18. Grignani F, de Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815-8.
19. Dhordain P, Lin RJ, Quief S, Lantoine D, Kerckaert JP, Evans RM, Albagli O,. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res 1998; 26: 4645-51.
20. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY,. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001; 92: 1300-4.
21. Fouladi M,. Histone deacetylase inhibitors in cancer therapy. Cancer Invest 2006; 24: 521-7.
22. Roy S, Packman K, Jeffrey R, Tenniswood M,. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 2005; 12: 482-91.
23. Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, Bates S, Fojo T,. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 2005; 65: 7386-92.
24. Yamaguchi K, Lantowski A, Dannenberg AJ, Subbaramaiah K,. Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. J Biol Chem 2005; 280: 32569-77.
25. Duan H, Heckman CA, Boxer LM,. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 2005; 25: 1608-19.
26. Tsurutani J, Soda H, Oka M, Suenaga M, Doi S, Nakamura Y, Nakatomi K, Shiozawa K, Amada YY, Kamihira S, Kohno S,. Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines. Int J Cancer 2003; 104: 238-42.
27. Sowa Y, Orita T, Hiranabe-Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T,. Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites. Ann NY Acad Sci 1999; 886: 195-9.
28. Richon VM, Sandhoff TW, Rifkind RA, Marks PA,. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000; 97: 10014-9.
29. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B,. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
30. Jackson PK, Chevalier S, Philippe M, Kirschner MW,. Early events in DNA replication require cyclin E and are blocked by p21CIP1. J Cell Biol 1995; 130: 755-69.
31. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ,. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-16.
32. Levine AJ,. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.
33. Waga S, Hannon GJ, Beach D, Stillman B,. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-8.